204 related articles for article (PubMed ID: 33030957)
1. Loss of tumor intrinsic PD-L1 confers resistance to drug-induced apoptosis in human colon cancer.
Feng D; Chen Z; He X; Huang S; Zhang Z
Neoplasma; 2021 Jan; 68(1):144-153. PubMed ID: 33030957
[TBL] [Abstract][Full Text] [Related]
2. BRAF
Feng D; Qin B; Pal K; Sun L; Dutta S; Dong H; Liu X; Mukhopadhyay D; Huang S; Sinicrope FA
Oncogene; 2019 Oct; 38(41):6752-6766. PubMed ID: 31406255
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability.
Korehisa S; Oki E; Iimori M; Nakaji Y; Shimokawa M; Saeki H; Okano S; Oda Y; Maehara Y
Int J Cancer; 2018 Feb; 142(4):822-832. PubMed ID: 29044503
[TBL] [Abstract][Full Text] [Related]
4. Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer.
Zhang P; Kawakami H; Liu W; Zeng X; Strebhardt K; Tao K; Huang S; Sinicrope FA
Mol Cancer Res; 2018 Mar; 16(3):378-389. PubMed ID: 29233910
[TBL] [Abstract][Full Text] [Related]
5. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ
Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906
[TBL] [Abstract][Full Text] [Related]
6. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
[TBL] [Abstract][Full Text] [Related]
7. The effects of ARID1A mutations on colorectal cancer and associations with PD-L1 expression by stromal cells.
Kamori T; Oki E; Shimada Y; Hu Q; Hisamatsu Y; Ando K; Shimokawa M; Wakai T; Oda Y; Mori M
Cancer Rep (Hoboken); 2022 Jan; 5(1):e1420. PubMed ID: 34042312
[TBL] [Abstract][Full Text] [Related]
8. PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies.
Lin KX; Istl AC; Quan D; Skaro A; Tang E; Zheng X
Cancer Immunol Immunother; 2023 Dec; 72(12):3875-3893. PubMed ID: 37831146
[TBL] [Abstract][Full Text] [Related]
9. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
[TBL] [Abstract][Full Text] [Related]
10. Increased CD8 Tumor Infiltrating Lymphocytes in Colorectal Cancer Microenvironment Supports an Adaptive Immune Resistance Mechanism of PD-L1 Expression.
Sudoyo AW; Kurniawan AN; Kusumo GD; Putra TP; Rexana FA; Yunus M; Budiyati AD; Kurniawan D; Utama A; Utomo AR
Asian Pac J Cancer Prev; 2019 Nov; 20(11):3421-3427. PubMed ID: 31759368
[TBL] [Abstract][Full Text] [Related]
11. 5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers.
Van Der Kraak L; Goel G; Ramanan K; Kaltenmeier C; Zhang L; Normolle DP; Freeman GJ; Tang D; Nason KS; Davison JM; Luketich JD; Dhupar R; Lotze MT
J Immunother Cancer; 2016; 4():65. PubMed ID: 27777774
[TBL] [Abstract][Full Text] [Related]
12. Characterisation of PD-L1-positive subsets of microsatellite-unstable colorectal cancers.
Kim JH; Park HE; Cho NY; Lee HS; Kang GH
Br J Cancer; 2016 Aug; 115(4):490-6. PubMed ID: 27404452
[TBL] [Abstract][Full Text] [Related]
13. Histopathologic and Molecular Biomarkers of PD-1/PD-L1 Inhibitor Treatment Response among Patients with Microsatellite Instability‒High Colon Cancer.
Hyung J; Cho EJ; Kim J; Kim JH; Kim JE; Hong YS; Kim TW; Sung CO; Kim SY
Cancer Res Treat; 2022 Oct; 54(4):1175-1190. PubMed ID: 35038827
[TBL] [Abstract][Full Text] [Related]
14. Immune environment in serrated lesions of the colon: intraepithelial lymphocyte density, PD-1, and PD-L1 expression correlate with serrated neoplasia pathway progression.
Acosta-Gonzalez G; Ouseph M; Lombardo K; Lu S; Glickman J; Resnick MB
Hum Pathol; 2019 Jan; 83():115-123. PubMed ID: 30172913
[TBL] [Abstract][Full Text] [Related]
15. Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer.
Brauner E; Gunda V; Vanden Borre P; Zurakowski D; Kim YS; Dennett KV; Amin S; Freeman GJ; Parangi S
Oncotarget; 2016 Mar; 7(13):17194-211. PubMed ID: 26943572
[TBL] [Abstract][Full Text] [Related]
16. Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer: Post Hoc Analysis of the CLASSIC Randomized Controlled study.
Choi YY; Kim H; Shin SJ; Kim HY; Lee J; Yang HK; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Choi SH; Hong S; Kim JW; Hyung WJ; Noh SH; Cheong JH
Ann Surg; 2019 Aug; 270(2):309-316. PubMed ID: 29727332
[TBL] [Abstract][Full Text] [Related]
17. Nuclear PD-L1 promotes cell cycle progression of BRAF-mutated colorectal cancer by inhibiting THRAP3.
Ma R; Liu Y; Che X; Li C; Wen T; Hou K; Qu X
Cancer Lett; 2022 Feb; 527():127-139. PubMed ID: 34923044
[TBL] [Abstract][Full Text] [Related]
18. Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients.
Nikanjam M; Arguello D; Gatalica Z; Swensen J; Barkauskas DA; Kurzrock R
Int J Cancer; 2020 Jun; 146(11):3087-3097. PubMed ID: 31479512
[TBL] [Abstract][Full Text] [Related]
19. Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer.
Kawakami H; Huang S; Pal K; Dutta SK; Mukhopadhyay D; Sinicrope FA
Mol Cancer Ther; 2016 Dec; 15(12):3015-3027. PubMed ID: 27765849
[TBL] [Abstract][Full Text] [Related]
20. Hyperresponsiveness to interferon gamma exposure as a response mechanism to anti-PD-1 therapy in microsatellite instability colorectal cancer.
Yuan W; Deng D; Jiang H; Tu C; Shang X; He H; Niu R; Dong J
Cancer Immunol Immunother; 2019 Feb; 68(2):257-268. PubMed ID: 30406373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
